18 December 2024NewsAmericasRajiv Nayar, President, HTD Biosystems | Chuck Sholtz, Vice President, Intellectual Property, Nutcracker Therapeutics | Benjamin Pelletier, Partner, Haynes & Boone

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

Speakers from HTD Biosystems, Nutcracker Therapeutics, and Haynes & Boone examine the evolving patent landscape for biologics, biosimilars, and bispecific antibodies, sharing practical strategies and jurisdiction-specific insights.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Americas
10 July 2026   Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science.
Americas
9 July 2026   Separate lawsuits target Indian and Taiwanese pharma companies as Exelixis seeks to keep rival cabozantinib products off the US market until key patents expire.
Americas
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.